In fact, clinical trials with some inhibitors or antibodies for molecular targets, such as gefitinib (a small-molecule EGFR inhibitor), cetuximab (an anti-EGFR antibody), and trastuzumab (an anti-HER2 antibody), were performed for patients with salivary gland carcinomas. This evidence concerns the gene ERBB2 and salivary gland carcinoma.